Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., announce that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). In connection with the proposed merger, the companies secured commitments for an oversubscribed concurrent private placement of $150 million from a syndicate of leading healthcare-dedicated investors.
Read the full article: Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150M Private Placement //
Source: https://www.globenewswire.com/news-release/2026/08/21/3349035/0/en/werewolf-therapeutics-and-ambros-therapeutics-announce-merger-agreement-and-concurrent-oversubscribed-150-million-private-placement.html?_gl=1*wld5zc*_up*MQ..*_ga*ODQyNTU3MDIzLjE3ODczMTQ5OTk.*_ga_ERWPGTJ5X8*czE3ODczMTQ5OTkkbzEkZzAkdDE3ODczMTQ5OTkkajYwJGwwJGgw*_ga_B6167QB2TF*czE3ODczMTQ5OTkkbzEkZzAkdDE3ODczMTQ5OTkkajYwJGwwJGgxNzI5MDk0MTI5